CARDINNOV - Research targeting development of innovative therapeutic strategies in cardiovascular disease 2023

– MARGINALIZE-MI

Résumé de soumission

Acute Myocardial Infarction, commonly known as a heart attack, is one of the leading causes of death globally, and the cost of healthcare for patients with this type of heart disease is estimated to be in the billions of euros annually. Recent evidence highlights the instrumental roles of the inflammatory reaction in the alteration of cardiac function after a heart attack.
This project seeks to develop a new therapeutic approach targeting a population of inflammatory cells to improve cardiac function after a heart attack. More precisely, we will develop an immunotherapy strategy through the development of antibodies directed against the deleterious inflammatory cells in order to eliminate them. We will first characterize these harmful inflammatory cells, then we will develop specific antibodies directed against these cells and finally we will test their therapeutic effectiveness on the function of the cardiac muscle after a myocardial infarction. In other words, we will seek to repair the broken heart by reducing its inflamed state.

Coordination du projet

Jean-Sebastien Silvestre (PARIS CENTRE DE RECHERCHE CARDIOVASCULAIRE)

L'auteur de ce résumé est le coordinateur du projet, qui est responsable du contenu de ce résumé. L'ANR décline par conséquent toute responsabilité quant à son contenu.

Partenariat

PARCC PARIS CENTRE DE RECHERCHE CARDIOVASCULAIRE

Aide de l'ANR 298 209 euros
Début et durée du projet scientifique : mai 2024 - 36 Mois

Liens utiles

Explorez notre base de projets financés

 

 

L’ANR met à disposition ses jeux de données sur les projets, cliquez ici pour en savoir plus.

Inscrivez-vous à notre newsletter
pour recevoir nos actualités
S'inscrire à notre newsletter